FN1 and neoplasm: In addition, the combined treatment of Fn-OMV and oHSV significantly increased the release of nuclear high mobility group box 1 (HMGB1) (Fig. 5e) and tumor necrosis factor-alpha (TNF-α) (Fig. 5f) in tumor cells compared to oHSV treatment alone.